C. GRACE YEH, PhD
Chairman and Chief Executive Officer
Grace is one of the three founders, CEO and Chairman of Onward Therapeutics SA. Currently, she is on the board of Biomunex Pharmaceuticals SAS and EMERCell SAS. She also serves as Vice Chairman, Taiwan Biotechnology Industry Organization.
From 2003 to 2019, she was Founder, President and CEO of PharmaEngine, a publicly traded commercial stage oncology company (TWO:4162) headquartered in Taipei, Taiwan with a wholly owned subsidiary in Paris, France. Its market capitalization on the Taipei Exchange exceeded US$1 billion in 2015.
Prior to returning to Taiwan, she served in senior positions from 1988 to 2002, at Millennium Pharmaceuticals, LeukoSite, CytoMed, and T Cell Sciences, all based in Cambridge, MA, USA. Before joining the industry, she worked in academic research at INSERM (National Institutes of Health and Medical Research) in France; and Blond Mclndoe Centre for Transplantation Biology in England.
Approved products: ONYVIDE® and HENSIFY®.
Grace received her Ph.D. in Immunology from Medical University of South Carolina, USA. She was given the EY Entrepreneur of the Year Award in 2016.
She also became the first female Laureate of the Industrial Technology Research Institute in 2021.